Why the study?
Hypertriglyceridemia levels vary greatly among monoallelic LPL variant carriers, and it remained unclear whether and to what extent heterozygotes in the Polish population display clinical symptoms.
Do heterozygotes for pathogenic variants in the LPL gene exhibit severe clinical symptoms and hypertriglyceridemia comparable to homozygotes?
Do heterozygotes for pathogenic variants in the LPL gene exhibit severe clinical symptoms and hypertriglyceridemia comparable to homozygotes?
Heterozygous carriers of pathogenic LPL variants can exhibit severe hypertriglyceridemia and related clinical symptoms (e.g., pancreatitis) traditionally associated only with homozygous LPL deficiency.
Introduction Biallelic pathogenic variants in the LPL gene are associated with familial lipoprotein lipase (LPL) deficiency. Homozygotes exhibit very severe hypertriglyceridemia (HTG) already in childhood with phenotypic features, such as pancreatitis, abdominal pain and xanthomata. Recent studies showed that HTG levels varied greatly between monoallelic LPL pathogenic/likely pathogenic variant carriers. The aim of our study is to investigate whether heterozygotes for pathogenic variants in the LPL gene in the Polish population may have clinical symptoms and to what extent. Material and methods Genetic data derived from the Polish cohort of 5623 whole exome sequenced patients. In 52 cases the indication for WES genetic testing was “hypertriglyceridemia '' and for 5571 there was another clinical indication, mainly autism spectrum disorder, dysmorphia and neurodegenerative diseases. Results We present 22 heterozygous and 2 homozygous/compound heterozygotes individuals for the pathogenic/likely pathogenic LPL variant and describe HTG levels, phenotypic manifestations and age of onset in the context of molecular findings where available. We report for the first time heterozygous LPL individuals with a very severe TG (TG ≥ 22.6 mmol/L; >2000 mg/dL) and additional symptoms such as pancreatitis and recurrent abdominal pain. Conclusions We argue that although the individuals carrying the single LPL pathogenic/likely pathogenic variant display the whole disease spectrum, the severe phenotype of heterozygotes dominant LPL-related HTG may also exists.
No takes yet. Share an insight, caveat, or question.
Szczęśniak et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: